Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

BACKGROUND: The efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear. METHODS: We randomly assigned, in a 1:1 ratio, hospitalized adults with Covid-19 pneumonia to receive either tofacitinib at a...

Descripción completa

Detalles Bibliográficos
Autores principales: Guimarães, Patrícia O., Quirk, Daniel, Furtado, Remo H., Maia, Lilia N., Saraiva, José F., Antunes, Murillo O., Kalil Filho, Roberto, Junior, Vagner M., Soeiro, Alexandre M., Tognon, Alexandre P., Veiga, Viviane C., Martins, Priscilla A., Moia, Diogo D.F., Sampaio, Bruna S., Assis, Silvia R.L., Soares, Ronaldo V.P., Piano, Luciana P.A., Castilho, Kleber, Momesso, Roberta G.R.A.P., Monfardini, Frederico, Guimarães, Helio P., Ponce de Leon, Dario, Dulcine, Majori, Pinheiro, Marcia R.T., Gunay, Levent M., Deuring, J. Jasper, Rizzo, Luiz V., Koncz, Tamas, Berwanger, Otavio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220898/
https://www.ncbi.nlm.nih.gov/pubmed/34133856
http://dx.doi.org/10.1056/NEJMoa2101643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220898/
https://www.ncbi.nlm.nih.gov/pubmed/34133856
http://dx.doi.org/10.1056/NEJMoa2101643

Ejemplares similares